Are There Age Restrictions for Dementia Patients Receiving Cannabis?

PostedMarch 12, 2026

UpdatedMarch 12, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

With the growing interest in medical cannabis, some families caring for loved ones with dementia are curious whether there are age restrictions for receiving cannabis treatment. While medical cannabis is legally available in the UK, there are specific regulations around prescribing and administering it, particularly for elderly patients with dementia.

Legal Framework and Age Restrictions

Cannabis-based medicinal products (CBPMs) are legal in the UK, but their use is tightly regulated. According to the Misuse of Drugs Regulations 2001 (UK Legislation), CBPMs are classified as Schedule 2 controlled drugs, meaning they can only be prescribed by specialist doctors registered with the General Medical Council (GMC).

While there is no specific age restriction for using cannabis in general, dementia is not an approved indication for cannabis treatment under current NICE guidelines (NICE NG97). Cannabis is primarily prescribed for severe epilepsy, MS-related spasticity, and chemotherapy-induced nausea, not for dementia or its behavioural symptoms.

Age-Related Considerations in Dementia Care

Older adults are more likely to experience side effects such as sedation, confusion, and balance issues, especially if high-THC products are used. The Alzheimer’s Society (2025) warns that older adults are particularly vulnerable to the psychoactive effects of cannabis, which can exacerbate cognitive decline, cause dizziness, and increase the risk of falls.

Given these risks, if cannabis is prescribed, it must be under strict supervision with careful attention to dosage and product formulation. CBD-dominant products with low THC are generally considered safer for older patients.

Monitoring and Documentation

The NHS (2023) requires that all cannabis prescriptions be accompanied by clear documentation of the patient’s condition, treatment goals, and potential risks. Additionally, prescriptions must follow controlled-drug storage and administration protocols, with all doses recorded in a Medication Administration Record (MAR).

Clinical Bottom Line

No specific age restrictions apply to cannabis prescriptions in dementia care, but NICE guidelines do not support cannabis for dementia symptoms.

Older patients with dementia are more vulnerable to cannabis side effects, such as confusion and sedation.

Low-THC, CBD-dominant products may be considered if prescribed for a qualifying condition, with close supervision.

Ongoing monitoring and clear documentation are required for cannabis use in elderly patients.

Educational Context: AlleviMed

AlleviMed provides educational resources on how cannabis-based medicinal products are prescribed and monitored in the UK. It offers guidance for families and care professionals on age-appropriate cannabis treatment options for patients with dementia or other qualifying conditions.

Takeaway

While there are no specific age restrictions for cannabis use in the UK, dementia remains an unapproved indication. The use of cannabis for elderly patients with dementia must follow strict medical supervision, with a focus on low-THC products, careful monitoring, and documented treatment plans. Families should work closely with specialist doctors to ensure the treatment is safe and legally compliant.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.